ANIX · XBRL financial data

Anixa Biosciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ANIX's year ends in late October)

In thousands of dollars	FY 2020Oct 31, 2020	FY 2022Oct 31, 2021	FY 2022Oct 31, 2022	FY 2023Oct 31, 2023	FY 2024Oct 31, 2024	FY 2025Oct 31, 2025
Revenue	—	513	—	210	210	—
Revenue from contracts with customers	—	513	—	210	—	—
Research and development	4,381	6,190	6,703	4,769	6,396	5,071
General and administrative	5,597	7,073	7,172	6,291	7,435	6,630
Operating income (loss)	(9,978)	(13,136)	(13,875)	(11,011)	(13,831)	(11,701)
Net income (loss)	(10,018)	(12,954)	(13,595)	(9,811)	(12,554)	(10,927)
Earnings per share, basic USD per share	—	(0.45)	(0.45)	0.32	(0.39)	(0.34)
Earnings per share, diluted USD per share	—	—	0.45	0.32	(0.39)	(0.34)
Weighted average shares, basic thousands of shares	—	—	30	31	32	32
Weighted average shares, diluted thousands of shares	—	28,579	30,374	31	32	32

Fiscal years (ANIX's year ends in late October)

In thousands of dollars	FY 2020Oct 31, 2020	FY 2022Oct 31, 2021	FY 2022Oct 31, 2022	FY 2023Oct 31, 2023	FY 2024Oct 31, 2024	FY 2025Oct 31, 2025
Cash and cash equivalents	6,417	29,128	12,360	915	1,271	1,244
Short-term investments	2,640	6,600	17,327	22,929	18,653	13,930
Prepaid and other current assets	309	276	513	1,242	1,265	713
Total current assets	9,369	36,003	30,200	25,356	21,362	15,887
Right-of-use asset	54	254	212	166	229	193
Total assets	9,453	36,257	30,412	25,522	21,591	16,080
Accounts payable	232	136	265	206	525	165
Accrued liabilities	901	1,095	1,726	1,770	1,946	1,761
Total current liabilities	1,189	1,271	2,037	2,028	2,500	1,967
Lease liability, non-current	—	220	175	123	203	163
Total liabilities	1,189	1,491	2,212	2,151	2,703	2,130
Accumulated deficit	(191,836)	(204,790)	(218,385)	(228,196)	(240,750)	(251,677)
Total stockholders' equity	8,761	35,437	29,047	24,337	19,998	15,161
Total liabilities and equity	9,453	36,257	30,412	25,522	21,591	16,080
Common shares outstanding (cover page) thousands of shares	26,077	30,132	30,921	31,700	32,197	33,377

Fiscal years (ANIX's year ends in late October)

In thousands of dollars	FY 2020Oct 31, 2020	FY 2022Oct 31, 2021	FY 2022Oct 31, 2022	FY 2023Oct 31, 2023	FY 2024Oct 31, 2024	FY 2025Oct 31, 2025
Net income (loss)	(10,018)	(12,954)	(13,595)	(9,811)	(12,554)	(10,927)
Stock-based compensation	3,923	7,503	6,000	4,422	4,420	3,681
Net cash from operating activities	(6,176)	(4,937)	(6,492)	(6,209)	(7,335)	(7,173)
Purchases of property and equipment	16	—	—	—	—	—
Net cash from investing activities	(306)	(3,918)	(10,728)	(5,602)	4,276	4,866
Proceeds from issuing common stock	9,266	10,834	—	—	2,955	2,378
Share repurchases	—	—	—	—	6	—
Net cash from financing activities	9,407	31,566	452	366	3,415	2,280
Net change in cash	2,925	22,711	(16,768)	(11,445)	356	(27)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Anixa Biosciences	1,398	not reported	(1,770)*	34.8M	6.8 quarters	Q3 FY26 10-QJul 31, 2026
Entera Bio	11,309	0	(3,464)*	173.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Filana Therapeutics	46,990	not reported	(6,094)*	50.3M	7.5 quarters	Q3 FY26 10-QSep 30, 2026
Immunic	155,098	not reported	(30,998)*	13.6M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Coherus Oncology	82,923	not reported	(62,090)*	154.5M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Elicio Therapeutics	30,900	not reported	(10,364)*	28.3M	3.1 quarters	Q3 FY26 10-QSep 30, 2026
GENELUX	9,184	not reported	(6,444)*	45.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Oramed Pharmaceuticals	15,245	not reported	(200)*	41.6M	189.8 quarters	Q2 FY26 10-QJun 30, 2026
XBiotech	109,528	not reported	(4,515)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 3:27 PM ET. The filing on SEC.gov is the record.